Jon E. Angell

Array ( [id] => 9964309 [patent_doc_number] => 09011919 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Compositions for targeted delivery of siRNA' [patent_app_type] => utility [patent_app_number] => 13/615938 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 6 [patent_no_of_words] => 24548 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13615938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9656703 [patent_doc_number] => 20140227708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-14 [patent_title] => 'METHODS AND KITS USED IN IDENTIFYING MICRORNA TARGETS' [patent_app_type] => utility [patent_app_number] => 14/236619 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 23216 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14236619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9983810 [patent_doc_number] => 09029525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-12 [patent_title] => 'Compositions and methods for inhibiting expression of GSK-3 genes' [patent_app_type] => utility [patent_app_number] => 13/615164 [patent_app_country] => US [patent_app_date] => 2012-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 73618 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13615164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11930913 [patent_doc_number] => 09797904 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers' [patent_app_type] => utility [patent_app_number] => 14/428334 [patent_app_country] => US [patent_app_date] => 2012-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 9775 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8618134 [patent_doc_number] => 20130023446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'siRNA Targeting Beta Secretase (BACE)' [patent_app_type] => utility [patent_app_number] => 13/613910 [patent_app_country] => US [patent_app_date] => 2012-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 35295 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13613910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8638239 [patent_doc_number] => 20130030042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'NUCLEIC ACIDS FOR TARGETING MULTIPLE REGIONS OF THE HCV GENOME' [patent_app_type] => utility [patent_app_number] => 13/602886 [patent_app_country] => US [patent_app_date] => 2012-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22020 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13602886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8710317 [patent_doc_number] => 20130067606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'MODULATING PRODUCTION TRAITS IN AVIANS' [patent_app_type] => utility [patent_app_number] => 13/602927 [patent_app_country] => US [patent_app_date] => 2012-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10205 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13602927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8586972 [patent_doc_number] => 20130005794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-03 [patent_title] => 'METHODS AND SEQUENCES TO SUPPRESS PRIMATE HUNTINGTON GENE EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/601198 [patent_app_country] => US [patent_app_date] => 2012-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 13851 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13601198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8708769 [patent_doc_number] => 20130066058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1' [patent_app_type] => utility [patent_app_number] => 13/572123 [patent_app_country] => US [patent_app_date] => 2012-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 101 [patent_figures_cnt] => 101 [patent_no_of_words] => 33090 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13572123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9183418 [patent_doc_number] => 08623350 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2014-01-07 [patent_title] => 'Protease inhibitor: protease sensitivity expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria' [patent_app_type] => utility [patent_app_number] => 13/562488 [patent_app_country] => US [patent_app_date] => 2012-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 11288 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13562488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8685145 [patent_doc_number] => 20130053428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-28 [patent_title] => 'NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS' [patent_app_type] => utility [patent_app_number] => 13/563581 [patent_app_country] => US [patent_app_date] => 2012-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 40600 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13563581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10176230 [patent_doc_number] => 09206425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-08 [patent_title] => 'Methods for treating Niemann-Pick type C disease' [patent_app_type] => utility [patent_app_number] => 14/235482 [patent_app_country] => US [patent_app_date] => 2012-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 7230 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14235482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9662326 [patent_doc_number] => 08809294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-19 [patent_title] => 'Method of inhibiting miR-33 using a modified oligonucleotide' [patent_app_type] => utility [patent_app_number] => 13/540097 [patent_app_country] => US [patent_app_date] => 2012-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 136678 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13540097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9462732 [patent_doc_number] => 20140127159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-08 [patent_title] => 'HCV Combination Therapy' [patent_app_type] => utility [patent_app_number] => 14/128504 [patent_app_country] => US [patent_app_date] => 2012-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26837 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14128504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9635524 [patent_doc_number] => 20140213632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'HCV Combination Therapy' [patent_app_type] => utility [patent_app_number] => 14/128508 [patent_app_country] => US [patent_app_date] => 2012-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26725 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14128508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8442272 [patent_doc_number] => 20120258888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'siRNA Targeting Proto-oncogene MET' [patent_app_type] => utility [patent_app_number] => 13/494360 [patent_app_country] => US [patent_app_date] => 2012-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 35026 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13494360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8464715 [patent_doc_number] => 20120269883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'MicroRNA-140-5P as a Tumor Suppressor and Sensitizing Agent for Chemotherapy' [patent_app_type] => utility [patent_app_number] => 13/453553 [patent_app_country] => US [patent_app_date] => 2012-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14862 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13453553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8406549 [patent_doc_number] => 20120238618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'Pharmaceutical Composition Comprising Anti-miRNA Antisense Oligonucleotides' [patent_app_type] => utility [patent_app_number] => 13/415685 [patent_app_country] => US [patent_app_date] => 2012-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39595 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13415685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11263492 [patent_doc_number] => 09487778 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Oligonucleotide modulators of the toll-like receptor pathway' [patent_app_type] => utility [patent_app_number] => 14/002901 [patent_app_country] => US [patent_app_date] => 2012-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45899 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14002901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8442382 [patent_doc_number] => 20120258999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'Reagents, Methods and Systems to Suppress Pro-Inflammatory Cytokines' [patent_app_type] => utility [patent_app_number] => 13/369419 [patent_app_country] => US [patent_app_date] => 2012-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6854 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13369419 [rel_patent_id] =>[rel_patent_doc_number] =>)